A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
Epistemonikos ID: 41cf08ffc3aff0e861806793cf37ae23f03db676
First added on: May 02, 2026